Get the Stockscreener App
76.46
1.19%
0.90
After Hours:
77.00
0.54
+0.71%
Mirum Pharmaceuticals Inc stock is traded at $76.46, with a volume of 833.96K.
It is up +1.19% in the last 24 hours and up +11.65% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$75.56
Open:
$75.08
24h Volume:
833.96K
Relative Volume:
1.24
Market Cap:
$3.95B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-47.43
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
-3.03%
1M Performance:
+11.65%
6M Performance:
+52.01%
1Y Performance:
+77.44%
1-Day Range:
$74.40
$76.65
1-Week Range:
$73.82
$80.14
52-Week Range:
$36.88
$82.58
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
76.46 | 3.91B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Should You Invest in Mirum Pharmaceuticals (MIRM)? - Insider Monkey
Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - ADVFN
Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Aug Reactions: Will Mirum Pharmaceuticals Inc. stock pay special dividendsStop Loss & Reliable Volume Spike Alerts - moha.gov.vn
Price-Driven Insight from (MIRM) for Rule-Based Strategy - Stock Traders Daily
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now - Finviz
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - Yahoo Finance
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - The Motley Fool
Rice Hall James & Associates LLC Sells 67,247 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals price target raised to $88 from $80 at Baird - MSN
What Analysts Think Is Changing the Story for Mirum Pharmaceuticals Now - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Mirum pharmaceuticals director Saira Ramasastry sells $400k in shares By Investing.com - Investing.com Australia
Mirum Pharma director Grey sells $3.9 million in stock By Investing.com - Investing.com Nigeria
Mirum pharmaceuticals director Saira Ramasastry sells $400k in shares - Investing.com
Mirum Pharmaceuticals Executives Sell Shares - TradingView — Track All Markets
Mirum Pharma director Grey sells $3.9 million in stock - Investing.com
This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone - Investor's Business Daily
Mirum Pharmaceuticals joins elite list of stocks with 95-plus composite rating - MSN
Guidance Update: Will Mirum Pharmaceuticals Inc 08D stock sustain uptrend momentumPortfolio Return Summary & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So (MIRM) - Seeking Alpha
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 (NASDAQ:MIRM) - Seeking Alpha
Squarepoint Ops LLC Decreases Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
How (MIRM) Movements Inform Risk Allocation Models - Stock Traders Daily
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryTrade Risk Summary & Real-Time Market Trend Scan - Улправда
Signal Recap: Will Mirum Pharmaceuticals Inc. (08D) stock hit Wall Street targets2025 Market WrapUp & Verified Momentum Watchlists - Улправда
Will Mirum Pharmaceuticals Inc. stock pay special dividends2025 Macro Impact & Risk Adjusted Buy and Sell Alerts - Улправда
How Mirum Pharmaceuticals Inc. stock compares to growth peersMarket Growth Summary & Low Drawdown Momentum Trade Ideas - Улправда
Mirum Pharmaceuticals Surges Following Strategic Moves and Analyst Ratings - timothysykes.com
Mirum Pharmaceuticals Raises Capital via Private Placement - The Globe and Mail
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsM&A Rumor & High Accuracy Trade Signal Alerts - Улправда
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week High Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals: Bluejay Acquisition Boost - StocksToTrade
Citizens Maintains Mirum Pharmaceuticals (MIRM) Market Outperform Recommendation - Nasdaq
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval - Investing.com
Mirum Files Patent Suits to Block Livmarli Generics - TipRanks
Mirum Pharmaceuticals stock hits all-time high at 78.55 USD By Investing.com - Investing.com Nigeria
Mirum secures $68.5 million in private placement ahead of acquisition By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock hits all-time high at 78.55 USD - Investing.com
Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target - ts2.tech
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Up 8.9% Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX - Investing News Network
Mirum Pharmaceuticals announces additional private placement financing with TCGX - marketscreener.com
Mirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement - marketscreener.com
Mirum secures $68.5 million in private placement ahead of acquisition - Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $140.00 - MarketBeat
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mirum Pharmaceuticals Inc Stock (MIRM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ramasastry Saira | Director |
Dec 22 '25 |
Sale |
80.00 |
5,000 |
400,000 |
0 |
| GREY MICHAEL G | Director |
Dec 19 '25 |
Option Exercise |
2.94 |
50,000 |
146,800 |
50,000 |
| GREY MICHAEL G | Director |
Dec 19 '25 |
Sale |
78.00 |
50,000 |
3,900,000 |
0 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):